Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (4788 companies, A–Z).
Veradermics reported positive topline 12-month results from Part B of Study '302', a Phase 2/3 trial of its lead candidate VDPHL01 in 519 men with mild-to-moderate pattern hair loss, and reported no new safety signals. The filing covers clinical trial data only and includes no revenue, earnings, or guidance figures, and the drug has not been approved for sale.
Non-vellus hair count rose 43.9 hairs/cm2 (twice daily) and 29.7 hairs/cm2 (once daily) from baseline to Month 12 in the continued group.
At Month 12, 89.1% (twice daily) and 79.8% (once daily) of continued-group participants reported visible improvement in hair coverage on the AAIRS scale.
No treatment-related serious adverse events and no adverse event-related study discontinuations were reported between Month 6 and Month 12.
The company plans to announce data from Study '306' in women in the first half of 2027.
Vir Biotechnology said its pivotal Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart in adults with chronic hepatitis delta met its primary and key secondary endpoints, with data presented at the AASLD Liver Meeting on November 8, 2026. The company also released expanded Phase 2 SOLSTICE data and preliminary, exploratory findings on treatment discontinuation, which the company itself says are interim and not a complete assessment of safety or efficacy.
ECLIPSE 1 primary endpoint: 44% of patients on elebsiran and tobevibart reached undetectable virus plus ALT normalization at Week 48, versus 0% in the delayed treatment group at Week 12 (p<0.0001)
Key secondary endpoint: 79% reached undetectable virus at Week 48, versus 0% in the delayed treatment group
SOLSTICE Week 96: 100% (28/28) of patients who completed Week 96 of combination therapy reached undetectable viremia
Exploratory analysis: 10 patients discontinued treatment; all 10 achieved SVR12, with 7 reaching SVR24 and 1 reaching SVR48; the filing states these data are preliminary and not a claim of cure
ImmunityBio said its ANKTIVA plus BCG combination met the primary efficacy endpoint in Cohort A of the randomized QUILT-2.005 trial in BCG-naive non-muscle invasive bladder cancer, with 370 subjects. The company plans to submit a supplemental Biologics License Application to the FDA by year-end 2026, which could expand ANKTIVA's indication to earlier-stage patients.
Trial of 370 subjects compared ANKTIVA plus BCG with BCG alone; the combination showed a statistically significant efficacy improvement in carcinoma in situ patients.
No treatment-related deaths were reported; common adverse events were consistent with BCG alone.
Supplemental BLA is on track for FDA submission by year-end 2026; more study details will be presented at an upcoming medical congress.
Edesa Biotech entered a Collaboration and License Agreement dated November 8, 2026, giving Kyorin Pharmaceutical exclusive rights to develop and sell paridiprubart for ARDS in Japan, while Edesa keeps rights elsewhere, including the United States, Europe and Canada. The deal provides a $12 million upfront payment, milestone payments and royalties, and Edesa also gave notice that it is terminating its at-the-market share sales agreement with H.C. Wainwright, effective November 16, 2026.
Kyorin pays a one-time, non-refundable upfront payment of $12 million
Development and regulatory milestones of up to $55 million, plus sales-based milestones of up to ¥12.0 billion
Kyorin pays tiered, low double-digit royalties on net sales in Japan
ATM agreement with H.C. Wainwright terminated effective November 16, 2026, with no termination penalties
MetaVia said interim Part 3B data from its Phase 1 trial of DA-1726 showed a 68% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss after 16 weeks, with 15 DA-1726-treated and four placebo participants in the interim analysis. The company said the results support a planned 48-week Phase 2 study in up to 150 patients with MetALD and ALD, targeted to begin in the second half of 2027, but the sample is small and full data are not due until the first quarter of 2027.
Liver fat (MRI-PDFF) fell 68% placebo-adjusted at Day 109 (p<0.001); all five participants with baseline steatosis fell below 5%
Body weight fell 13.5% placebo-adjusted (p<0.001); HbA1c fell 0.24 percentage points versus placebo (p=0.006) in participants without diabetes
One serious adverse event, severe vomiting, was considered possibly related to treatment; the participant recovered
Full Part 3A and 3B data expected in Q1 2027; Phase 2 study targeted to start in 2H 2027
On October 29, 2026, Symbotic and Walmart entered an Enterprise Master Automation Agreement under which Walmart made an initial commitment of approximately $6 billion to purchase Symbotic systems and fund development programs over several years. The agreement covers automation for 25 U.S. regional distribution centers and additional markets, and Symbotic expects the commitment could increase its future backlog by up to $6.92 billion. For shareholders, the deal deepens a large customer relationship and gives Walmart board recommendation and observer rights tied to its ownership and revenue share.
Initial commitment of approximately $6 billion over several years, which may not be reduced without mutual written consent
Symbotic expects the commitment could raise its future backlog by up to $6.92 billion
Walmart committed $125 million to fund next-generation racking and related technology development
Walmart may recommend one board nominee while holding more than 5% of fully diluted equity, and may name two non-voting observers if it represents more than 50% of consolidated revenue
Solaris Energy Infrastructure's subsidiary agreed on October 29, 2026 to provide about 900 megawatts of power generation, balance of plant equipment and operations and maintenance services to an existing investment-grade industrial and technology customer. The agreement has an initial 15-year term per deployment, with an option to extend for another 15 years, and deployments are expected to begin in the first half of 2027 and scale through 2028.
Capacity covered: approximately 900 megawatts of power generation
Initial term: 15 years for each deployment, with an option to extend 15 more years
Timing: deployments expected to begin in the first half of 2027 and scale through 2028
Customer: a leading, investment-grade, diversified industrial and technology company that is already a Company customer
Forward Air entered a definitive two-year agreement with one of its largest customers, which will keep using the company for a significant portion of its current services. Certain other services will be transitioned away between November 2026 and March 2027, and the company says this is not expected to materially affect 2026 revenue. The company expects annual revenue from the customer in each contract year from 2026 to 2028 to exceed the customer's total 2025 revenue contribution, which management says should bring more visibility and predictability to the business.
Two-year agreement covers a significant portion of services currently provided to one of the largest customers
Transition of certain services expected between November 2026 and March 2027
Transition not expected to materially impact 2026 revenue
Annual revenue from the customer expected to exceed its 2025 total contribution in each year from 2026 to 2028
Trust Stamp said it signed a three-year agreement with Nigerian technology provider BLIP Limited to supply AI-powered identity verification for government registration programs in Nigeria. The company describes it as one of its largest deployments to date, but the filing states the agreement includes no revenue guarantee, so shareholders cannot yet rely on its financial contribution.
Initial term of three years, extendable by the parties; BLIP's Nigerian government engagement or a breach could end it early.
Management believes year-three revenue could be $3 million to $5 million, but the agreement does not guarantee any revenue.
Deployment is expected to exceed one million enrollments in its first year, with programs covering a population of tens of millions.
Agreement signed by the company and BLIP; press release issued October 26, 2026, and the 8-K filed October 27, 2026.
Climb Bio presented initial PrisMN Phase 2 data for budoprutug in primary membranous nephropathy at ASN Kidney Week 2026, with the 200 mg cohort showing B-cell depletion, PLA2R antibody reduction and immunologic remission at Week 12. The results were consistent with Phase 1b data, and the 600 mg cohort showed greater drug exposure and deeper B-cell suppression at Week 4, but the cohorts are small and follow-up is limited, and the company expects additional Phase 2 data in 2027.
200 mg cohort: mean PLA2R antibody reduction of 70% at Week 12; five of 13 patients (38%) achieved immunologic remission
Patients with baseline PLA2R antibody levels below 175 RU/mL had a mean reduction of 80% at Week 12
600 mg cohort: mean peripheral CD20+ B-cell suppression of 98% at Week 4, compared with 74% at 200 mg
Budoprutug was generally well tolerated in the 200 mg and 600 mg cohorts; no treatment-related serious adverse events were reported
Tempus AI announced agreements with Bristol-Myers Squibb and Pathos AI to expand use of its de-identified real-world data, software and models, with aggregate cash payments to Tempus of $192.5 million over about five years. The Pathos neurology deal is a related-party transaction, reviewed and approved by a special committee of disinterested directors, which shareholders may weigh when assessing the agreements.
BMS oncology Statement of Work runs through December 31, 2031, with $137.5 million in fixed payments invoiced quarterly.
Pathos Neuro Order Form provides up to $55 million, including $100 per delivered record and $5.0 million for record updates; the total depends on records delivered.
Pathos is a related party because of overlapping executive leadership and equity ownership, so a special committee of disinterested directors approved the neurology deal.
ORIC Pharmaceuticals presented updated Phase 1b data for its enozertinib (ORIC-114) program at ESMO Congress 2026 on October 23, 2026, reporting an 84% investigator-assessed systemic response rate and a 70% investigator-assessed intracranial response rate in 26 patients with EGFR atypical NSCLC. The company plans to start a global Phase 3 trial, Redwood-1, in the first half of 2027. The filing contains clinical data only and no financial results, so the update's effect on shareholders depends on future trial outcomes and funding.
Investigator-assessed systemic ORR was 84% (21 of 25); BICR-assessed systemic ORR was 80% (20 of 25) as of the September 4, 2026 cutoff
BICR RANO-BM intracranial ORR was 67% (10 of 15), with a 40% (6 of 15) complete response rate
Six patients (23%) had Grade 3 treatment-related adverse events, all resolved with dose modifications; no Grade 4 or 5 events were reported
Redwood-1 Phase 3 trial plans to enroll approximately 360 patients, with initiation planned for the first half of 2027
Zymeworks signed a Collaboration and License Agreement with Roche on October 22, 2026, giving Roche exclusive worldwide rights to develop and commercialize its ZW209 DLL3-targeting trispecific T-cell engager. The deal includes a $55 million upfront payment and up to $718 million in milestones, and it takes effect only after U.S. Hart-Scott-Rodino clearance, while Roche can terminate at any time.
Upfront non-refundable payment of $55 million, due after HSR Clearance
Non-refundable $40 million milestone on initiation of the Phase Ib Trial, plus up to $718 million in other milestones
Tiered high-single-digit to mid-teen royalties on annual net sales, with Zymeworks conducting the Phase Ia trial at Roche's expense
Roche may terminate the agreement in its sole discretion at any time; Zymeworks' exclusivity restriction runs up to five years
The FDA approved Hibsago (bepirovirsen), developed by GSK under a 2019 license from Ionis, for chronic hepatitis B in adults without cirrhosis who have suppressed HBV DNA and HBsAg levels of 3,000 IU/ml or less. Ionis has received an upfront payment, license fee and development and regulatory milestone payments, and is eligible for additional milestones and tiered royalties of 10-12% on net sales.
Phase 3 B-Well trials showed a 19% functional cure rate (233 of 1,220) versus 0 of 614 in the placebo group, in adults with HBsAg of 3,000 IU/ml or less
Current standard of care alone typically achieves less than 1% functional cure after one year of treatment, according to the filing
The approval followed FDA priority review and Breakthrough Therapy Designation; the filing states about 1.7 million people in the U.S. have chronic hepatitis B
The label includes boxed warnings for on-treatment hepatic flares and thrombocytopenia
Roivant and its subsidiary Priovant reported that brepocitinib 45 mg met the primary endpoint and all key secondary endpoints in the two identical Phase 3 CLARITY-1 and CLARITY-2 trials in non-infectious uveitis, with 371 patients enrolled. Priovant plans to file a supplemental New Drug Application for NIU in the first half of calendar 2027, which would be the next step toward a possible new treatment for the condition. The filing furnishes the press release under Regulation FD and contains no financial results.
Primary endpoint (time to treatment failure) met in CLARITY-1 (N=166) and CLARITY-2 (N=204); 371 patients enrolled in total
Median time to treatment failure was greater than 48 weeks in both studies, versus about 12 weeks on placebo (p<0.0001 in both)
Pooled, 62% of brepocitinib patients achieved steroid-free quiescence at Week 48, versus 20% on placebo
Priovant intends to file the sNDA in the first half of calendar 2027; Roivant investor call set for 8:00 a.m. ET on October 21, 2026
Hallador Energy's subsidiary Hallador Power signed a six-year power purchase agreement and a capacity credit sale agreement with Duke Energy Indiana, both covering output from the Merom Generating Station from June 1, 2029 through May 31, 2035. The filing says Duke Energy Indiana will pay approximately $271 million for the capacity credits over the term, and the company's press release puts total forward sales at $3 billion. The deals lock in future revenue for much of Merom's output but require standby letters of credit and are unit contingent.
Capacity agreement: 225 ZRCs per day on average, with Duke Energy Indiana paying approximately $271 million over the six-year term
Energy agreement: 200 MW annual average base energy quantity, unit contingent, with the company estimating about $422 million of energy revenue at current forward prices
Standby letters of credit: $3.5 million for the PPA rising to $7.0 million in January 2029, and $6 million for the MPPSA rising to $12 million in January 2029
Press release says the agreements raise total forward sales to $3 billion; full agreements to be filed with the next Form 10-Q
Regeneron and Sanofi amended their antibody collaboration on October 1, 2026, to co-develop and co-commercialize four new long-acting antibodies. Sanofi will pay Regeneron a $1.0 billion upfront payment, with up to $7.0 billion more in milestones, and the two companies will share global profits equally. Regeneron also expects a third-quarter 2026 acquired IPR&D charge of about $22 million, or $0.18 per diluted share, and agreed to dismiss a lawsuit against Sanofi.
Sanofi will pay Regeneron a $1.0 billion upfront payment under the Sixth Amendment dated October 1, 2026.
Regeneron is eligible for up to an additional $7.0 billion in development, regulatory, and commercial milestone payments.
Regeneron expects a third-quarter 2026 acquired IPR&D charge of about $22 million pre-tax, reducing GAAP and non-GAAP EPS by about $0.18 per diluted share.
Regeneron agreed to dismiss its lawsuit over Sanofi's obligations to provide information on Dupixent commercialization and audit rights.
TeraWulf said its subsidiary signed amended and restated power agreements with Kentucky Power that raise contracted capacity at its Muskie Data Campus in Kentucky from 500 MW to 1 GW. The filing also says the second 500 MW phase is now planned for delivery in 2029 instead of 2030, subject to Kentucky Public Service Commission approval, and the company plans to seek more senior secured financing, with no assurance it will obtain it.
Contracted power at Muskie rises from 500 MW to 1 GW under agreements executed October 1, 2026.
Second 500 MW phase delivery moves from 2030 to 2029, subject to Kentucky Public Service Commission approval and Kentucky Power's construction schedule.
First 500 MW phase remains targeted to begin ramping in 2028.
TeraWulf plans to upsize its senior secured revolving credit facility and seek additional senior secured debt for letter of credit needs; the filing gives no assurance the financing will be obtained.
Vaxcyte said its pivotal Phase 3 OPUS-1 adult trial met all prespecified primary endpoints for VAX-31, its 31-valent pneumococcal conjugate vaccine candidate, compared with Prevnar 20 and Capvaxive. The company said the results will serve as the cornerstone of a planned Biologics License Application to the FDA, with results from OPUS-2 and OPUS-3 expected in the first half of 2027. The filing contains no revenue, earnings or cash figures, and the data remain subject to FDA review.
All 28 VAX-31 serotypes shared with PCV20 and/or PCV21 met the noninferiority criterion in adults 50 and older.
VAX-31 met noninferiority for 20 of 20 serotypes shared with PCV20 and 17 of 19 shared with PCV21; serotypes 3 and 12F missed the stricter criterion against PCV21.
OPUS-2 and OPUS-3 results are expected in the first half of 2027, and a Biologics License Application submission is planned for the first half of 2028.
Immix Biopharma said an interim update from its Phase 2 NEXICART-2 trial shows an 89% (40/45) complete response rate across all 45 enrolled relapsed/refractory AL Amyloidosis patients, as assessed by an independent review committee. The company said the final readout and BLA submission are planned for mid-2027, so the data remain interim and the therapy has not been approved.
Complete response rate of 89% (40/45) across all 45 enrolled patients, per an independent review committee
All 25 new patients are in complete response or MRD-negative (21 in CR, 4 MRD-negative)
Four MRD-negative patients still pending; the company says this could raise the CR rate to up to 98% (44/45)
Final readout and BLA submission planned for mid-2027; company reported no neurotoxicity or enterocolitis to date
SCYNEXIS entered a contract with the U.S. Biomedical Advanced Research and Development Authority to develop its SCY-247 antifungal candidate, with potential non-dilutive funding of up to $214 million if all options are exercised. The initial base period provides approximately $18.5 million to advance SCY-247 into a Phase 2 study in patients with invasive candidiasis. The company says its SCY-770 development plans and cash runway into 2029 are unchanged.
Contract signed September 25, 2026; base period starts September 2026 with approximately $18.5 million
Potential total funding up to $214 million; BARDA may exercise up to six options extending the term up to ten years
Cost-share arrangement; company expects to fund its share of near-term SCY-247 costs within its existing operating plan
Full contract to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026, with confidential terms redacted
Volato Group's Alignment Engine subsidiary signed a Master Services Agreement on September 22, 2026, with two initial orders for dedicated AMD GPU infrastructure at its Ohio AI campus, totaling approximately $1.17 billion in contract value. The filing says the customer has committed to about $133 million in contractual prepayments, and the orders run for 48 months on a take-or-pay basis, which the company describes as its first major customer commitment for the platform.
Two 48-month orders under the MSA with an aggregate contractual value of approximately $1.17 billion.
Initial deployment of AMD MI355X GPUs has a contractual start date of December 31, 2026; second deployment of AMD MI455X GPUs starts June 30, 2027.
Customer has committed to approximately $133 million in prepayments, including approximately $40 million due after execution of the initial order.
Either party may terminate for an uncured material breach after a 30-day cure period.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.